Celldex Therapeutics (CLDX) Amortizatization of Intangibles (2010 - 2026)

Celldex Therapeutics' Amortizatization of Intangibles history runs 17 years deep, the most recent figure standing at $630000.0 for Q1 2026.

• On a quarterly basis, Amortizatization of Intangibles fell 72.21% year-over-year to $630000.0 in Q1 2026; TTM through Mar 2026 was $4.2 million, a 71.31% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, down 62.82% from the prior year.
• Amortizatization of Intangibles declined to $630000.0 in Q1 2026 per CLDX's latest filing, from $882000.0 in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $4.7 million in Q2 2024 and bottomed at -$772000.0 in Q1 2022.
• The 5-year median for Amortizatization of Intangibles is $1.3 million (2023), against an average of $1.6 million.
• Across the five-year window, Amortizatization of Intangibles slumped 1708.33% in 2022 and soared 2905.17% in 2023, its largest moves.
• Year by year, Amortizatization of Intangibles stood at $522000.0 in 2022, then jumped by 317.43% to $2.2 million in 2023, then surged by 54.34% to $3.4 million in 2024, then tumbled by 73.77% to $882000.0 in 2025, then decreased by 28.57% to $630000.0 in 2026.
• Per Business Quant, the three latest CLDX Amortizatization of Intangibles figures stand at $630000.0 (Q1 2026), $882000.0 (Q4 2025), and $1.0 million (Q3 2025).